University Hospital Schleswig-Holstein

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

  NCT07291102· Phase 3· Nationwide Children's Hospital· Source

• Not yet recruiting

  Validation Of anatomY-specific Aortic Valve Implantation Guided by Software Using EncantoR

  NCT07696182· Abbott Medical Devices· Source

• Recruiting

  Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma

  NCT07825064· Phase 2· Hoffmann-La Roche· Source

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· Phase 3· Almirall, S.A.· Source

• Not yet recruiting

  A study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis

  2026-526184-38-00· Phase 2· Enveda Therapeutics Inc.· Source

• Recruiting

  Efanesoctocog alfa treatment in patients with congenital hemophilia A suffering from inflammation of joint lining

  2025-523896-44-00· Phase 3· GWT-Tud GmbH· Source

• Recruiting

  Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)

  2026-525489-23-00· Phase 3· Amgen Inc.· Source

• Recruiting

  Observational Study With CICR-NAM as a Food for Special Medicinal Purposes in Post-COVID Syndrome (PCS)

  NCT07798570· University Hospital Schleswig-Holstein· Source

• Recruiting

  A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC

  NCT07807163· Phase 2· Bicara Therapeutics· Source

• Not yet recruiting

  AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

  2025-522190-11-01· Phase 3· Universitaetsklinikum Schleswig-Holstein AöR· Source

• Not yet recruiting

  Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.

  2026-526419-13-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· AstraZeneca· Source

• Recruiting

  FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS

  NCT07674667· Phase 1/2· Trace Neuroscience, Inc.· Source

• Recruiting

  A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma

  NCT05314998· Phase 3· Universitaetsklinikum Heidelberg AöR· Source

• Recruiting

  BGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer

  NCT07492641· Phase 3· BeOne Medicines I GmbH· Source

• Not yet recruiting

  Augmented Reality Aided Remote Access and Technical Support for Complex Ablation Procedures

  NCT07777042· University of Luebeck· Source

• Not yet recruiting

  Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed, Moderate-to-severe Crohn's Disease

  NCT07659353· Phase 4· University Hospital Schleswig-Holstein· Source

• Recruiting

  A Study to Evaluate Targeted Therapies for Patients with Rheumatoid Arthritis

  2025-523127-21-00· Phase 1· AbbVie Deutschland GmbH & Co. KG· Source

• Recruiting

  The RAPID-Elapse study: Can the drug bupropion improve fatigue symptoms in patients with long COVID?

  2025-524443-12-00· Phase 2· Goethe University Frankfurt· Source

• Recruiting

  An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

  NCT07665437· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

  NCT07516951· Phase 2· Chiesi Farmaceutici S.p.A.· Source

• Recruiting

  A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.

  NCT07672236· Phase 3· OncoZenge AB· Source

• Not yet recruiting

  Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?

  2026-525513-31-00· Phase 3· Norges Teknisk-Naturvitenskapelige Universitet NTNU· Source

• Not yet recruiting

  GMMG-HD11/DSMM XXI/64007957MMY3010

  NCT07671287· Phase 3· University of Heidelberg Medical Center· Source

• Recruiting

  A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT07690371· Phase 3· Nektar Therapeutics· Source

• Recruiting

  Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

  NCT07555938· Phase 3· Hoffmann-La Roche· Source

• Enrolling by invitation

  Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

  NCT07652294· Phase 2· Spyre Therapeutics, Inc.· Source

• Not yet recruiting

  Valvosoft Outcomes Registry for Real-World Evidence

  NCT07520591· Cardiawave SA· Source

• Recruiting

  Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year

  2025-521590-13-00· Phase 3· Janssen Cilag International· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

  NCT07571174· Phase 1· Eli Lilly and Company· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  Impact of Diet on the Microbiome-Immune-Brain Axis in Parkinson's Disease

  NCT06463769· University of Kiel· Source

• Active, not recruiting

  A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

  2025-522440-41-00· Phase 2· Bluefin Biomedicine Inc.· Source

• Recruiting

  Rapid Microaxial Flow Pump Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock and Persistent Need of Hemodynamic Support

  NCT07655479· University Hospital of Cologne· Source

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants

  2025-521762-99-00· Phase 3· University Medical Center Hamburg-Eppendorf· Source

• Active, not recruiting

  Evaluation of efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes

  2025-521670-34-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

  NCT07449702· Phase 2· Oruka Therapeutics, Inc.· Source

• Recruiting

  A Pivotal Study Evaluating Safety and Effectiveness of Adaptative Tip Catheter in Patients With Acute Ischemic Stroke

  NCT07367100· Neuravi Limited· Source

• Not yet recruiting

  Investigation of the Effects of Oxidized Antigens on the T-Cell Response and the Epigenetic Reprogramming of Neutrophils in Lung Diseases - OXIGENE -

  NCT07386912· Research Center Borstel· Source

• Active, not recruiting

  Phase IIB Study of PHENOGENE-1A (Cromolyn) as an Adjuvant Therapy in Mild to Moderate ALS

  2025-520688-42-00· Phase 2· Phenonet Inc.· Source

• Not yet recruiting

  IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

  2025-521908-22-00· Phase 2/3· Bristol-Myers Squibb Services Unlimited Company· Source

• Recruiting

  A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa

  NCT07384975· Phase 2· Navigator Medicines, Inc.· Source

• Active, not recruiting

  A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

  NCT07277660· Phase 2· UCB Biopharma SRL· Source

• Recruiting

  Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.

  2024-512503-39-00· Phase 4· Medizinische Hochschule Hannover· Source

• Recruiting

  STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

  NCT07280585· Phase 3· University of Cologne· Source

Showing 50 of 256.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers19 recruiting
• Crohn's disease14 recruiting
• Acute lymphoblastic leukaemia10 recruiting
• Atopic dermatitis (eczema)9 recruiting
• Heart failure7 recruiting
• Lung cancer7 recruiting
• Multiple myeloma7 recruiting
• Ulcerative colitis7 recruiting
• Acute myeloid leukaemia6 recruiting
• Chronic lymphocytic leukaemia6 recruiting
• Aortic stenosis5 recruiting
• Melanoma5 recruiting
• Psoriasis5 recruiting
• Atrial fibrillation4 recruiting
• Hidradenitis suppurativa4 recruiting
• Mantle cell lymphoma4 recruiting
• Stroke4 recruiting
• Bronchiectasis3 recruiting
• COPD3 recruiting
• Coronary artery disease3 recruiting
• Head and neck cancer3 recruiting
• Metastatic breast cancer3 recruiting
• Myelodysplastic syndromes3 recruiting
• Parkinson disease3 recruiting
• ALS (motor neurone disease)2 recruiting
• Bladder cancer2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Follicular lymphoma2 recruiting
• High blood pressure2 recruiting
• Long COVID and ME/CFS2 recruiting
• Lupus (SLE)2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Prostate cancer2 recruiting
• Rheumatoid arthritis2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Vitiligo2 recruiting
• Alopecia areata1 recruiting
• Alzheimer disease1 recruiting
• Amyloidosis1 recruiting
• Asthma1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• Chronic myeloid leukaemia1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Colorectal cancer1 recruiting
• Cystic fibrosis1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Endometrial cancer1 recruiting
• Essential tremor1 recruiting
• Haemophilia1 recruiting
• Huntington's disease1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Liver and biliary tract cancer1 recruiting
• Liver cirrhosis1 recruiting
• Neuroblastoma1 recruiting
• Obesity1 recruiting
• Osteoporosis1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Polycystic kidney disease1 recruiting
• Sarcoidosis1 recruiting
• Sarcoma1 recruiting
• Triple-negative breast cancer1 recruiting
• Tuberculosis1 recruiting

Closed trials

• Recruiting

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· Phase 3· Incyte Corporation· Source

• Completed

  Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07)

  NCT06984328· Phase 2· Genmab A/S· Source

• Active, not recruiting

  A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis

  NCT06975722· Phase 2· Sanofi· Source

• Completed

  A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer (NeoTRACE)

  2024-517561-16-00· Phase 2· AIO-Studien gGmbH· Source

• Active, not recruiting

  A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  NCT06291220· Phase 1· AbbVie· Source

• Completed

  Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermatitis.

  NCT06447506· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

  NCT06433219· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa

  2024-511363-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Completed

  How Metabolism Affects Weight Loss and Gain

  NCT06860776· University Hospital Schleswig-Holstein· Source

• Active, not recruiting

  Phase IIa Study Evaluating AZD7798 in Crohn's Disease

  NCT06450197· Phase 2· AstraZeneca· Source

• Completed

  Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis

  2023-508679-34-00· Phase 2· Anaptysbio Inc.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06586112· Phase 3· Alumis Inc· Source

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source

• Completed

  Randomized adaptive assessment of post COVID syndrome treatments (RAPID) Reducing Inflammatory Activity in Patients with post COVID Syndrome (REVIVE)

  2024-511628-16-00· Phase 2· Goethe University Frankfurt· Source

• Completed

  A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.

  NCT06431763· Phase 4· Novartis Pharmaceuticals· Source

• Completed

  A clinical study comparing different doses of a potential new medicine with an inactive medicine for patients with moderate to severe psoriasis

  2023-508992-35-00· Phase 2· Janssen Cilag International· Source

• Completed

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis

  2023-506655-19-00· Phase 2· Genentech Inc.· Source

• Active, not recruiting

  A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

  NCT06407934· Phase 3· Sanofi· Source

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Erasca, Inc.· Source

• Completed

  Kinetics and Metabolism of Nicotinamide Provided as a Dietary Supplementation

  NCT07156929· University Hospital Schleswig-Holstein· Source

• Completed

  A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC injection in Adult Participants with Moderate to Severe Atopic Dermatitis

  NCT05999799· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  Regorafenib-pembrolizumab vs. TACE/TARE in intermediate-stage HCC beyond up-to-7.

  NCT04777851· Phase 3· Translational Research In Oncology· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

  NCT06257875· Phase 2· AbbVie· Source

• Completed

  A proof of concept and dose-finding study of XXB750 in patients with heart failure

  2023-504678-39-00· Phase 2· Novartis Pharma AG· Source

• Completed

  A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

  2023-506092-10-00· Phase 2· Ascendis Pharma Oncology Division A/S· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

  NCT06224348· Phase 3· Sanofi· Source

• Terminated

  Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

  NCT05999968· Phase 1· Eli Lilly and Company· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Completed

  Safety, tolerability, and efficacy of ACOU085 for prevention of hearing loss in testicular cancer patients receiving cisplatin

  NCT06521190· Phase 2· Acousia Therapeutics GmbH· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

  NCT06130566· Phase 3· Sanofi· Source

• Terminated

  The RECOVER IV Trial

  NCT05506449· Abiomed Inc.· Source

• Completed

  A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

  2023-505558-16-00· Phase 3· Almirall S.A.· Source

• Active, not recruiting

  A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

  NCT06045806· Phase 3· Celgene· Source

• Completed

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

  NCT05923099· Phase 2· LEO Pharma· Source

• Terminated

  Metabolic Phenotyping for Personalized Obesity Therapy

  NCT06874270· University Hospital Schleswig-Holstein· Source

• Completed

  Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis

  NCT05672199· Phase 2· Amgen Inc.· Source

• Completed

  Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (NeoTreme)

  2024-515660-31-00· Phase 2· Universitaetsklinikum Schleswig-Holstein AöR· Source

• Completed

  Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

  NCT05804032· Phase 3· University of Heidelberg Medical Center· Source

• Completed

  Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions

  NCT05499832· Phase 3· Insel Gruppe AG, University Hospital Bern· Source

• Completed

  Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy)

  NCT05675319· Phase 3· University Medical Center Hamburg-Eppendorf· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Withdrawn

  Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1

  NCT05219864· Phase 3· Incyte Corporation· Source

• Completed

  Cardiac safety of treosulfan chemotherapy prior to stem cell transplantation in patients with leukemia.

  2024-517377-24-00· Phase 1· Medac Gesellschaft fuer klinische Spezialpraeparate mbH· Source

• Completed

  Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION)

  2023-508528-36-00· Phase 3· Merck Healthcare KGaA· Source

• Completed

  Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

  NCT05092360· Phase 3· Mural Oncology Inc.· Source

• Completed

  A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

  NCT05651711· Phase 3· Amgen· Source

• Terminated

  A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

  NCT05529316· Phase 2· Agenus Inc.· Source

• Completed

  Study on the Performance of Symmcora® Mid-term Suture Versus Novosyn® Suture in Patients Undergoing Robotic Assisted Gastric Bypass Surgery

  NCT05433688· Aesculap AG· Source

Showing 50 of 104.

Conditions

Diseases this institution publishes on or runs trials for.

• Atrial fibrillation73 works · 4 trials
• Parkinson disease70 works · 4 trials
• Atopic dermatitis (eczema)52 works · 23 trials
• Psoriasis47 works · 13 trials
• Melanoma41 works · 21 trials
• Crohn's disease38 works · 25 trials
• Ulcerative colitis36 works · 29 trials
• Acute lymphoblastic leukaemia36 works · 16 trials
• Acute myeloid leukaemia32 works · 13 trials
• Ventricular tachycardia31 works · 1 trial
• Multiple myeloma24 works · 11 trials
• Dystonia17 works · 0 trials
• Congenital heart disease15 works · 0 trials
• Hodgkin lymphoma15 works · 3 trials
• Bronchiectasis14 works · 3 trials
• Aortic stenosis14 works · 9 trials
• Brain aneurysm11 works · 1 trial
• Aortic aneurysm10 works · 1 trial
• Essential tremor9 works · 1 trial
• Mantle cell lymphoma9 works · 5 trials
• Vitiligo6 works · 3 trials